Mesoblast (ASX:MSB) today released their corporate review showing how the company will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry.
Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe.
And Mesoblast has recently entered into a strategic cardiovascular partnership for China with Tasly Pharmaceutical Group, China’s leading cardiovascular company.
Shares in Mesoblast (ASX:MSB) trading 5.77 per cent higher at $1.10.
